The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 02, 2024

Filed:

May. 27, 2020
Applicant:

Gpcr Therapeutics, Inc., Seoul, KR;

Inventors:

DongSeung Seen, Seoul, KR;

Eunhee Kim, Seoul, KR;

Jae-Yeon Jeong, Seoul, KR;

Chang Soo Yang, Seoul, KR;

Milim Lee, Seoul, KR;

SoHui Kim, Seoul, KR;

Won-Ki Huh, Seoul, KR;

Yong Bhum Song, Daejeon, KR;

Chul O Park, Seoul, KR;

Hyeryung Park, Seoul, KR;

Jiyeong Lee, Seoul, KR;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/19 (2006.01); A61K 31/403 (2006.01); A61K 31/138 (2006.01); A61K 31/395 (2006.01); A61P 35/00 (2006.01); A61K 31/451 (2006.01); A61K 31/495 (2006.01); A61K 31/5415 (2006.01); A61K 31/4545 (2006.01); A61K 31/47 (2006.01); A61K 38/12 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01);
U.S. Cl.
CPC ...
A61K 38/195 (2013.01); A61K 31/138 (2013.01); A61K 31/395 (2013.01); A61K 31/403 (2013.01); A61K 31/451 (2013.01); A61K 31/4545 (2013.01); A61K 31/47 (2013.01); A61K 31/495 (2013.01); A61K 31/5415 (2013.01); A61K 38/12 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07K 16/286 (2013.01); C07K 16/2866 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/21 (2013.01); C07K 2317/76 (2013.01);
Abstract

This invention relates to inhibitors of CXC receptor 4 (CXCR4)-G protein-coupled receptor (GPCR) heteromers (CXCR4-GPCR heteromers) associated with cancers, where CXCR4 forms a functional heteromer with other G protein-coupled receptors (GPCRx). More specifically, this invention relates to GPCRx that form heteromers with CXCR4, which upon co-stimulation with CXCR4 agonists and GPCRx agonists leads to enhanced signaling downstream of CXCR4. This invention also provides for the use of inhibitors of the interacting GPCR partner of the CXCR4-GPCRx heteromer or CXCR4-GPCRx heteromer-specific inhibitors including inhibitors of the formation of the CXCR4-GPCRx heteromer and CXCR4-GPCRx heteromer-specific antibodies, and in the diagnosis and/or therapy for cancer.


Find Patent Forward Citations

Loading…